Cryosite Limited (ASX:CTE – Get Free Report) insider Mark Kerr sold 154,494 shares of the business’s stock in a transaction on Friday, June 21st. The stock was sold at an average price of A$1.05 ($0.70), for a total transaction of A$162,218.70 ($108,145.80).
Mark Kerr also recently made the following trade(s):
- On Tuesday, April 23rd, Mark Kerr purchased 1,000,000 shares of Cryosite stock. The stock was bought at an average cost of A$0.83 ($0.55) per share, with a total value of A$830,000.00 ($553,333.33).
Cryosite Price Performance
The company has a debt-to-equity ratio of 87.26, a quick ratio of 1.76 and a current ratio of 2.32.
Cryosite Company Profile
Cryosite Limited offers outsourced clinical trials logistic services in Australia. It operates through two segments, Clinical Trials and Biological Services Logistics, and Cord Blood and Tissues Storage. The Clinical Trials and Biological Services Logistics segment provides specialist temperature-controlled storage, sourcing, labelling, status management, secondary packaging, schedule drug distribution, destruction, returns and biological, as well as logistics services to the clinical trials, research, and pharmaceutical industries.
Featured Stories
- Five stocks we like better than Cryosite
- Stock Sentiment Analysis: How it Works
- Qualcomm Stock: AI-Powered Growth Despite Volatility
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Salesforce Stock: Meeting Recap, AI Focus, and Forecast
- What Are Dividend Contenders? Investing in Dividend Contenders
- Is CAVA Overextended? A Closer Look at This High-Flying Stock
Receive News & Ratings for Cryosite Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryosite and related companies with MarketBeat.com's FREE daily email newsletter.
